PDE5 inhibitor
Tadalafil
Tadalafil (Cialis) is a PDE5 inhibitor whose US label gives a mean terminal half-life of 17.5 hours in healthy subjects and a median time to peak of 2 hours.1
Tadalafil after one dose: 50% at ~17.5 h, 25% at 35 h, 12.5% at 52.5 h.
Drawn from the half-life in the app's model, ~17.5 h. The model's figures
- Compound
- Tadalafil
- Symbol
- CIA
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
The US label for Cialis, held by Eli Lilly and Company, lists tadalafil as a phosphodiesterase 5 (PDE5) inhibitor and gives 2003 as its initial US approval.1 Its three listed indications are erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and ED together with the signs and symptoms of BPH.1 The label's patient information describes Cialis as a prescription medicine taken by mouth.1 A separate US label, Adcirca, lists tadalafil as a PDE5 inhibitor indicated for pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise ability.2
A phase 3 trial in boys with Duchenne muscular dystrophy reported no effect on its primary outcome, and in a trial after nerve-sparing prostatectomy, unassisted erectile function after a drug-free washout was not improved, although the probability of recovery during treatment was higher on once-daily tadalafil than on placebo.3,4
How it works
Sources in this part
In people
The Cialis label states that penile erection during sexual stimulation is mediated by nitric oxide release, which stimulates the synthesis of cGMP in smooth muscle cells, and that inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.1 It adds that because sexual stimulation is required to start the local release of nitric oxide, the inhibition of PDE5 by tadalafil has no effect in the absence of sexual stimulation.1 For BPH the label states that the mechanism for reducing BPH symptoms has not been established.1
In laboratory tests
In vitro, the label reports tadalafil as more than 10,000-fold more potent for PDE5 than for PDE1, PDE2, PDE4 and PDE7, 700-fold for PDE6 and 14-fold for PDE11A1.1 It states that the physiological role and clinical consequence of PDE11 inhibition in humans have not been defined.1
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~17.5 h
- Bioavailability
- 95%
- Typical dose
- 2.5–10 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
| Measure | App figure | What the sources give |
|---|---|---|
| Half-life | ~17.5 hours | The Cialis label gives a mean terminal half-life of 17.5 hours in healthy subjects. The Adcirca label gives 15 hours after 40 mg in healthy subjects and 35 hours in patients with pulmonary hypertension not receiving bosentan.1,2 |
| Bioavailability (oral) | ~95% | Neither label gives a percentage: both state that absolute bioavailability of tadalafil following oral dosing has not been determined.1,2 |
| Time to peak | ~2 hours | The Cialis label gives a median of 2 hours, in a range of 30 minutes to 6 hours. The Adcirca label gives a median of 4 hours, in a range of 2 to 8 hours.1,2 |
| Duration of effect | ~36 hours | The label states that Cialis for use as needed improved erectile function compared with placebo up to 36 hours following dosing, a statement about effect in trials, not about concentration.1 |
| Route | Oral | Cialis is supplied as tablets for oral administration in 5, 10 and 20 mg strengths, and Adcirca as 20 mg tablets.1,2 |
| Typical dose | 2.5 to 10 mg/day | The Cialis label lists 2.5 mg or 5 mg once daily for ED, 5 mg once daily for BPH, and 10 mg as a starting dose for use as needed in ED; the Adcirca label lists 40 mg once daily for PAH.1,2 |
In the Cialis label, exposure rose in proportion to dose over 2.5 to 20 mg in healthy subjects, absorption was not influenced by food, and steady-state concentrations were attained within 5 days of once-daily dosing at about 1.6-fold the exposure after a single dose.1 The chart below draws the app's one-compartment model with its half-life of 17.5 hours and time to peak of 2 hours, both of which match the Cialis label's figures for healthy subjects.1
Level over 1 weeks
Level, as a share of the peak after one 5 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 17.5 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Cialis label, US trials A and B (ED, as needed)1 | Randomized, double-blind, placebo-controlled, 12 weeks; label holder Eli Lilly and Company | 402 men with ED, mean age 59 | 20 mg as needed or placebo | IIEF erectile function score at endpoint 19.5 against 13.5 (study A) and 22.5 against 13.6 (study B), p under .001; successful maintenance of erection 50% against 25% and 64% against 23%.1 |
| Brock and colleagues, J Urol 20025 | Integrated analysis of 5 randomized, double-blind, placebo-controlled trials; no sponsor or limitations in the source text | 1,112 men, mean age 59, mild to severe ED | Placebo or 2.5 to 20 mg as needed, 12 weeks | At 20 mg the erectile function score rose 7.9 from baseline (p under 0.001 against placebo), and 81% reported improved erections against 35% on placebo; headache and dyspepsia were the most frequent adverse events.5 |
| Brock and colleagues, J Sex Med 20166 | Pooled analysis of 17 as-needed and 4 once-daily placebo-controlled studies; funded by Eli Lilly and Company | 4,354 men with ED | As needed 10 and 20 mg, or once daily 2.5 and 5 mg, 12 weeks | The 5 mg once-daily and the 10 and 20 mg as-needed doses improved erectile function (IIEF erectile function domain, placebo-adjusted) in every subgroup examined, with a weaker effect for 5 mg once daily in diabetes, while 2.5 mg did not in several; the paper's summary lists further exceptions in some subgroups, and the authors did not find clear evidence of a subgroup in which the as-needed regimen performed meaningfully better than the once-daily regimen.6 |
| Moncada and colleagues, World J Urol 20154 | Secondary analysis of a randomized, double-blind, double-dummy trial; authors list Eli Lilly affiliations and the text read states no funding | 139, 143 and 141 men randomized after bilateral nerve-sparing radical prostatectomy | 5 mg once daily, 20 mg as needed or placebo, 9 months, then a 6-week washout | Unassisted erectile function after the washout, a result the paper cites from the parent trial, was not improved by either regimen. In this analysis the probability of recovery (IIEF score of 22 or more) was higher on once daily than placebo (hazard ratio 1.9, 95% CI 1.2 to 3.1, p = 0.011) but not on as needed (p = 0.140); during the 9 months a score of 22 or more was reached by 29.5% (once daily), 23.9% (as needed) and 18.4% (placebo).4 |
| Roehrborn and colleagues, J Urol 20087 | Randomized, double-blind, placebo-controlled; registry lists Eli Lilly and Company as lead sponsor | 1,058 men with BPH lower urinary tract symptoms | Placebo or 2.5, 5, 10 or 20 mg once daily, 12 weeks | IPSS change from baseline was -2.3 on placebo against -3.9, -4.9, -5.2 and -5.2 on the four doses; no significant effect against placebo on peak flow at any dose.7 |
| Galie and colleagues, Circulation 2009 (PHIRST)8 | 16-week double-blind, placebo-controlled; registry lists Eli Lilly and Company as lead sponsor | 405 patients with PAH | Placebo or 2.5, 10, 20 or 40 mg once daily, 16 weeks | The 6-minute walk distance rose in a dose-dependent manner and only the 40 mg dose met the prespecified level (P under 0.01), with a placebo-corrected effect of 33 m (95% CI 15 to 50); WHO functional class changes were not statistically significant.8 |
| Victor and colleagues, Neurology 20173 | Phase 3, randomized, placebo-controlled, 63 sites in 15 countries; funded by Eli Lilly and Company; two authors are Eli Lilly employees | 331 boys aged 7 to 14 with Duchenne muscular dystrophy | 0.3 or 0.6 mg/kg a day or placebo, 48 weeks | The 48-week decline in 6-minute walk distance was 51.0 m on placebo, 64.7 m (p = 0.307) on the lower dose and 59.1 m (p = 0.538) on the higher dose; no effect on secondary outcomes.3 |
Deeper analysis: the label's as-needed ED trials
The Cialis label describes 7 randomized, multicenter, double-blind, placebo-controlled primary studies of 12 weeks in the general ED population, 2 in the United States and 5 elsewhere, with doses of 2.5 to 20 mg taken as needed up to once a day.1 The three primary outcomes were the erectile function domain of the International Index of Erectile Function (IIEF) and questions 2 and 3 of the Sexual Encounter Profile (SEP) diary.1 In the two US trials 20 mg gave statistically significant improvements on all three, and in the five trials outside the US the 5, 10 and 20 mg doses did the same, although in Study C one active-dose group had p = .063 against placebo on SEP question 2.1 The label's table footnote gives 6 months for Study F, against the 12 weeks stated for the seven studies.1 The label's five non-US studies and Brock 2002 both report 1,112 men in 5 trials, and the label's Study J and Roehrborn both report 1,058 men; the texts read do not say whether they are the same trials.1,5,7
Deeper analysis: once daily against as needed, Brock and colleagues 2016
Brock and colleagues (J Sex Med 2016) pooled 17 as-needed and 4 once-daily placebo-controlled studies in 4,354 men and wrote that all analyses were exploratory and without multiplicity adjustment.6 The authors stated that a direct comparison between the regimens is not possible because they were not studied head-to-head, that small subgroups limit conclusions, and that a difference in race between the groups can introduce bias.6 The paper states that the study was funded by Eli Lilly and Company, that its first author is on the advisory board and speaker's bureau for Eli Lilly and owns stock in it, and that one author is an employee and minor stockholder of Eli Lilly and another a former employee and minor stockholder.6
Deeper analysis: Roehrborn and colleagues, BPH dose-finding study, 2008
Roehrborn and colleagues randomized 1,058 men with BPH lower urinary tract symptoms, after a 4-week placebo run-in, to 12 weeks of once-daily placebo or tadalafil 2.5, 5, 10 or 20 mg.7 The International Prostate Symptom Score (IPSS) least-squares mean change was -2.3 on placebo and -3.9, -4.9, -5.2 and -5.2 on the four doses, with p = 0.015 at 2.5 mg and p under 0.001 at the higher doses.7 The authors reported no statistically significant effect on peak flow at any dose and described adverse events as infrequent in all tadalafil groups.7 The registry entry names Eli Lilly and Company as lead sponsor with ICOS Corporation as a collaborator, and the record read for the paper states no limitations.9 The label's study J randomized 1,058 patients to the same four doses or placebo, and its 5 mg group's total IPSS changed by -4.8 against -2.2 on placebo (p under .001), while maximum urinary flow rose 1.6 mL/sec against 1.2, a difference that was not significant.1
Deeper analysis: Galie and colleagues, PHIRST trial, 2009
The PHIRST study randomized 405 patients with pulmonary arterial hypertension, treatment-naive or on background bosentan, to placebo or tadalafil 2.5, 10, 20 or 40 mg once daily for 16 weeks, with the 6-minute walk distance as the primary end point.8 Only the 40 mg dose met the prespecified level of significance, with a placebo-corrected effect of 33 m overall, 44 m (95% CI 20 to 69) in the bosentan-naive group and 23 m (95% CI -2 to 48) in patients on background bosentan.8 For 40 mg the authors reported a 68% relative risk reduction in the incidence of clinical worsening (P = 0.038), and the most common treatment-related adverse events were headache, myalgia and flushing.8 The Adcirca label counts clinical worsening in 4 of 79 patients (5%) on 40 mg against 13 of 82 (16%) on placebo, with one death on placebo and one on the 10 mg dose.2 The registry names Eli Lilly and Company as lead sponsor with ICOS Corporation as a collaborator, and the record read for the paper states no limitations.10
Deeper analysis: Victor and colleagues, Duchenne muscular dystrophy trial, 2017
Victor and colleagues randomized 331 boys aged 7 to 14 with Duchenne muscular dystrophy (DMD) on glucocorticoids, 1:1:1, to placebo or tadalafil 0.3 or 0.6 mg/kg a day for 48 weeks, with the 6-minute walk distance as the primary measure.3 The authors reported "Tadalafil had no effect on the primary outcome," with declines of 51.0 m on placebo, 64.7 m on the low dose and 59.1 m on the high dose, and loss of ambulation in 7 boys (6.0%) on placebo, 16 (15.7%) on the low dose (p = 0.027) and 9 (8.0%) on the high dose.3 In the prespecified subgroup older than 10 years (n = 75), total upper-limb score declined 4% on placebo (n = 20) against 1% on the low dose (n = 33; p = 0.02), and tended to decline less on the high dose (n = 22) than on placebo (p above 0.1). The authors called the low-dose result hypothesis generating and of uncertain clinical significance, with an age-by-treatment interaction p value of 0.056.3 Adverse events related to the study drug were reported in 41.4%, 50.0% and 59.8% of patients on placebo, low and high dose (high dose against placebo p = 0.006), and no deaths occurred.3 The authors wrote that the negative result "stands in marked contrast to the solid preclinical foundation of the trial," and listed as limitations that the walk test is "invariably influenced by the boys' volition" and that the MRI and blood-flow substudies were too small to be informative.3 The trial was funded by Eli Lilly and Company, and the acknowledgments thank Eli Lilly staff for exposure analysis, scientific discussions and trial management.3 Two authors are Eli Lilly employees holding Lilly shares, and the global principal investigator reported contracted research, travel compensation and a consulting fee from Eli Lilly.3
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Cialis label, as needed for ED1 | 10 mg starting dose, changed to 20 or 5 mg | Up to once per day | Not stated |
| Cialis label, once daily for ED1 | 2.5 mg, increased to 5 mg | Once daily | Not stated |
| Cialis label, once daily for BPH, and ED with BPH1 | 5 mg | Once daily | With finasteride, up to 26 weeks |
| Adcirca label, PAH2 | 40 mg | Once daily | Not stated |
| Galie 2009 (PAH)8 | 2.5, 10, 20 or 40 mg | Once daily | 16 weeks |
Sources in this part
Side effects reported
In eight primary placebo-controlled studies of 12 weeks of as-needed Cialis in ED (mean age 59, range 22 to 88), the discontinuation rate due to adverse events was 3.1% with tadalafil 10 or 20 mg against 1.4% with placebo.1 The label lists the reactions reported by 2% or more of patients treated with 10 or 20 mg and more frequent than on placebo as headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and pain in limb, with these rates in the table, which also shows a 5 mg group.1
| Adverse reaction | Placebo (n=476) | 5 mg (n=151) | 10 mg (n=394) | 20 mg (n=635) |
|---|---|---|---|---|
| Headache | 5% | 11% | 11% | 15% |
| Dyspepsia | 1% | 4% | 8% | 10% |
| Back pain | 3% | 3% | 5% | 6% |
| Myalgia | 1% | 1% | 4% | 3% |
| Nasal congestion | 1% | 2% | 3% | 3% |
| Flushing | 1% | 2% | 3% | 3% |
| Pain in limb | 1% | 1% | 3% | 3% |
Sources in this part
For once-daily Cialis in ED (12 or 24 weeks, mean age 58) the discontinuation rate was 4.1% against 2.8% on placebo, and in BPH or ED with BPH trials of 12 weeks (mean age 63) it was 3.6% against 1.6%.1 The label states that in clinical pharmacology trials back pain or myalgia generally occurred 12 to 24 hours after dosing and typically resolved within 48 hours, and that changes in color vision were rare across all studies (under 0.1% of patients).1
The label's postmarketing section states that serious cardiovascular events, including myocardial infarction, sudden cardiac death and stroke, have been reported in temporal association with the use of tadalafil, most often in patients with preexisting cardiovascular risk factors, and that it is not possible to determine whether they are related directly to Cialis, to sexual activity or to other factors.1 It reports non-arteritic anterior ischemic optic neuropathy (NAION) rarely in temporal association with PDE5 inhibitors, cites an observational study of PDE5 inhibitor use as a class that suggests an approximate 2-fold increase in risk (risk estimate 2.15, 95% CI 1.06 to 4.34) and a similar study with a consistent result (2.27, 95% CI 0.99 to 5.20), and states that neither the reports nor the association substantiate a causal relationship.1 It also lists sudden decrease or loss of hearing, for which it is not possible to determine whether the events relate directly to the PDE5 inhibitor, and rare reports of prolonged erections greater than 4 hours and priapism.1
The label contraindicates Cialis with any form of organic nitrate, with guanylate cyclase stimulators such as riociguat, and in people with a known serious hypersensitivity to tadalafil.1 In a crossover study of 150 men aged at least 40 years (including some with diabetes mellitus and/or controlled hypertension) given tadalafil 20 mg or placebo for 7 days, a significant interaction with sublingual nitroglycerin was observed at each timepoint up to and including 24 hours, and by most hemodynamic measures not at 48 hours, although a few more tadalafil subjects than placebo had greater blood-pressure lowering at that timepoint.1 In the Adcirca label's placebo-controlled PAH trial, discontinuation because of an adverse event was 9% on 40 mg and 15% on placebo (4% and 5% when events related to worsening PAH are excluded), and headache was reported by 42% on 40 mg, 32% on 20 mg and 15% on placebo.2
Bloodwork and markers
Sources in this part
The Cialis label summarises three studies of tadalafil 10 mg or 20 mg daily for 6 to 9 months in which there were no adverse effects on sperm morphology or motility, and mean sperm concentrations fell relative to placebo in two of them (10 mg for 6 months and 20 mg for 9 months), a difference it calls not clinically meaningful, but not in the third (20 mg for 6 months).1 Elsewhere it states that the clinical significance of the decreased sperm concentrations in the two studies is unknown and that there have been no studies evaluating the effect of tadalafil on fertility in men.1 It reports no adverse effect on mean concentrations of testosterone, luteinizing hormone or follicle stimulating hormone with either dose compared with placebo.1 In the post hoc analysis of Goldfischer and colleagues (Urology 2014), in men with a partial response to an on-demand PDE5 inhibitor, tadalafil 2.5 mg titrated to 5 mg or 5 mg once daily (pooled) improved ED against placebo irrespective of testosterone level, with low defined as under 300 ng/dL, and the IIEF erectile function score improved significantly more in men with normal than low testosterone (P = .022); two of its authors list Lilly Research Laboratories as their affiliation.11 In the TADTEST trial of 173 men aged 45 to 80 who were nonresponders to PDE5 inhibitors and had low baseline testosterone, men not successful after 4 weeks of tadalafil 10 mg once daily were randomized to testosterone gel or placebo, and no additional effect of testosterone was seen overall; the difference from placebo was significant only in men with baseline testosterone of 3 ng/mL or less, and the record read for the trial states no sponsor.12 A single 100 mg dose, which the label puts at 5 times the highest recommended dosage, changed the mean QTc by 3.5 milliseconds (Fridericia correction; two-sided 90% CI 1.9 to 5.1) and 2.8 milliseconds (individual correction; two-sided 90% CI 1.2 to 4.4) relative to placebo in 90 healthy men.1
Regulatory and anti-doping status
Sources in this part
The WADA Prohibited List 2026 came into effect on 1 January 2026, and a text search of its document for tadalafil, sildenafil, phosphodiesterase and PDE5 returned no match.13
Storage and handling
Sources in this part
What is not known
Sources in this part
Both labels state that the absolute bioavailability of oral tadalafil has not been determined, and neither gives the app's 95%.1,2 The Cialis label states that the mechanism for reducing BPH symptoms has not been established, the clinical consequence of PDE11 inhibition in humans has not been defined, and, for tadalafil started with finasteride, the incremental benefit beyond 26 weeks is unknown.1 In the Duchenne trial the authors wrote that it remains unknown whether defective blood flow regulation during exercise in dystrophic human skeletal muscle remains a viable therapeutic target.3 A PubMed title search on 16 November 2026 for tadalafil together with bremelanotide or PT-141 returned no records.
Frequently asked questions
What is the half-life of tadalafil?
How long does tadalafil take to peak?
What is the bioavailability of tadalafil?
How long does tadalafil last?
Is tadalafil banned by WADA?
A text search of the WADA Prohibited List 2026 for tadalafil, sildenafil, phosphodiesterase and PDE5 returned no match.13
What are the most common side effects of tadalafil?
Did tadalafil work for Duchenne muscular dystrophy?
Does tadalafil change testosterone?
Guides, tools and comparisons
References
- Eli Lilly and Company. CIALIS- tadalafil tablet, film coated: US prescribing information. DailyMed, current version. DailyMed label
- United Therapeutics Corporation. ADCIRCA- tadalafil tablet: US prescribing information. DailyMed, revised 09/2020. DailyMed label
- Victor RG, Sweeney HL, Finkel R, et al. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology 2017. PMC5664308
- Moncada I, de Bethencourt FR, Lledó-García E, et al. Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy. World J Urol 2015. PMC4480825
- Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002. PMID 12352386
- Brock G, Ni X, Oelke M, et al. Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. J Sex Med 2016. PMC5411983
- Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008. PMID 18722631
- Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009. PMID 19470885
- ClinicalTrials.gov. NCT00384930: Study of tadalafil once-a-day for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia. Registry entry. NCT00384930
- ClinicalTrials.gov. NCT00125918: PHIRST-1, tadalafil in the treatment of pulmonary arterial hypertension. Registry entry. NCT00125918
- Goldfischer ER, Kim ED, Seftel AD, Baygani SK, Burns PR. Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. Urology 2014. PMID 24726311
- Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011. PMID 20704642
- World Anti-Doping Agency. World Anti-Doping Code International Standard, Prohibited List 2026. WADA list 2026